The price of an eighth of cannabis in the United States barely moved over the past year, inching up just seven cents nationally. But that stability masks dramatic variations between states—and new data suggests the number of dispensaries matters far more than whether a market is medical or recreational.
Washington state consumers pay around $15 for an eighth, while Kentucky patients face $52 for the same amount. The difference isn't explained by market structure or taxation alone. States with fewer than 25 dispensaries sell eighths at an average of $43.89, while states with more than 300 stores average $18.50—a $25 gap driven primarily by competition and market maturity.
Twenty-four of 34 tracked states lowered their average eighth prices over the past year, even as the national average held steady. The price compression reflects maturing markets in states like Colorado and Oregon, where dispensary saturation has driven down margins and forced retailers to compete aggressively on price.
The Medical Market Myth
Conventional wisdom holds that medical cannabis patients pay premium prices due to limited access and regulatory constraints. The raw numbers appear to support this: medical-only states show higher average prices than adult-use markets.
But when prices are weighted by actual sales volume—accounting for how much cannabis each state's market actually moves—the gap between medical and recreational markets shrinks to a single cent. Large medical markets like Florida and Ohio generate enough volume to bring their effective prices in line with recreational states, even if smaller medical programs show inflated figures.
The finding challenges assumptions about medical market pricing and suggests that volume and competition, not program type, determine what consumers ultimately pay.
Store Count Drives Everything
The data points to dispensary density as the primary price driver. States with mature markets and hundreds of licensed retailers benefit from competitive pressure that pushes prices down. Washington, Oregon, and Colorado—all with extensive retail networks—cluster at the bottom of the price range.
Meanwhile, newer or more restrictive markets with limited store counts see prices remain elevated. Kentucky's medical program, which launched recently with tight licensing caps, exemplifies the high-price, low-competition dynamic. Patients in these states effectively pay a premium for limited access.
The pattern holds across market types. Adult-use states with few dispensaries charge more than medical states with robust retail infrastructure. The correlation between store count and price proves stronger than any other factor tracked in the data.
What It Means for New Markets
The findings carry implications for states designing cannabis programs. Licensing caps and restrictive zoning—often justified as quality control measures—appear to inflate consumer prices without corresponding benefits. States that prioritize market access over artificial scarcity see faster price normalization.
For consumers, the message is clear: more stores mean lower prices. As newer markets mature and add licensed retailers, prices should trend downward regardless of whether the program is medical or recreational.
The national market's price stability, despite state-level variations, suggests the industry is reaching equilibrium in mature markets while newer programs still work through their growth phases.
This article is based on original reporting by hightimes.com.
